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Altered surface mGluR5 dynamics provoke
synaptic NMDAR dysfunction and cognitive defects
in Fmr1 knockout mice
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Metabotropic glutamate receptor subtype 5 (mGluR5) is crucially implicated in the patho-
physiology of Fragile X Syndrome (FXS); however, its dysfunction at the sub-cellular level,
and related synaptic and cognitive phenotypes are unexplored. Here, we probed the con-
sequences of mGluR5/Homer scaffold disruption for mGluR5 cell-surface mobility, synaptic
N-methyl-D-aspartate receptor (NMDAR) function, and behavioral phenotypes in the
second-generation Fmr1 knockout (KO) mouse. Using single-molecule tracking, we found that
mGluR5 was signiﬁcantly more mobile at synapses in hippocampal Fmr1 KO neurons, causing
an increased synaptic surface co-clustering of mGluR5 and NMDAR. This correlated with a
reduced amplitude of synaptic NMDAR currents, a lack of their mGluR5-activated long-term
depression, and NMDAR/hippocampus dependent cognitive deﬁcits. These synaptic and
behavioral phenomena were reversed by knocking down Homer1a in Fmr1 KO mice. Our study
provides a mechanistic link between changes of mGluR5 dynamics and pathological
phenotypes of FXS, unveiling novel targets for mGluR5-based therapeutics.
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Fragile X syndrome (FXS) is the most common form ofinherited intellectual disability and best-known cause ofautism1. In most cases FXS is caused by transcriptional
silencing of the FMR1 gene and the ensuing lack of encoded
Fragile X Mental Retardation Protein (FMRP) (reviewed in ref. 2),
an RNA-binding protein that regulates translation and trafﬁcking
of its interacting mRNAs in dendrites and axons (reviewed in
ref. 3). During the last decade numerous FMRP target mRNAs
have been identiﬁed4–7. In contrast, how changes in the expres-
sion of their protein products contribute to different features of
FXS pathology remains to be elucidated in detail (reviewed in
refs. 8–11). Studies from the Fmr1 knockout (KO) mouse model of
FXS provide compelling evidence that an increased expression of
a subset of synaptic proteins—and subsequent alteration in
synaptic plasticity—contribute to numerous cognitive phenotypes
of this disorder (reviewed in ref. 12). In particular, exaggerated
group-I metabotropic glutamate receptor subtype 5 (mGluR5)/
protein synthesis-dependent hippocampal long-term depression
(LTD) of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid receptor (AMPAR) currents is a hallmark feature of FXS13.
This seminal ﬁnding forms the basis of the mGluR theory of
FXS14. In support of this theory, correction of the aberrant
mGluR5 signaling through either pharmacological or genetic
means, leads to the rescue of a number of disease phenotypes
(reviewed in ref. 15).
Although much work has focused on the protein synthesis-
dependent functional consequences of inappropriate mGluR5
activation, other ﬁndings suggest that the intrinsic properties and
signal transduction mechanisms of mGluR5 might also be altered
in FXS (reviewed in ref. 16). Indeed, previous work has demon-
strated that the interaction between long Homer proteins and
mGluR5 is reduced in the absence of FMRP17, likely contributing
to an altered mGluR5-mediated signaling in Fmr1 KO mice18, 19.
The consequences of altered protein interactions for receptor
dynamics at synapses, however, remain to be investigated.
The dynamic movement of synaptic components has emerged
as a key feature of synaptic transmission and plasticity (reviewed
in refs. 20, 21). Indeed, receptors on the neuronal surface con-
stantly switch between mobile and immobile states, driven by
thermal agitation and reversible binding to stable elements such
as scaffolding proteins, cytoskeletal anchoring slots or extra-
cellular anchors (reviewed in ref. 22). The mobility of receptors
within the membrane may promote their interactions with other
synaptic receptors (reviewed in ref. 22), and its alteration might
also correlate with pathophysiological states, as recently suggested
for neurodegenerative disorders23, 24. Thus, an understanding of
the dynamics of receptors at Fmr1 KO synapses may provide
novel insights into the mechanisms underlying the synaptic
pathology in FXS.
Homer proteins are a family of post-synaptic density (PSD)
scaffolding proteins responsible for the link between mGluR5 and
other PSD proteins25. Both long (Homer1b/c, Homer2, and
Homer3, here collectively referred to as Homer) and short
(Homer1a) isoforms have been identiﬁed. The long Homer iso-
forms are constitutively expressed, multimerize, and link mGluR5
to signaling pathways within the PSD (reviewed in ref. 26).
Homer1a, on the other hand, is an immediate early gene indu-
cible by synaptic activity, which functions as a dominant negative
regulator of group-I mGluR signaling by disrupting the binding
between mGluR5 and Homer27, 28. Interestingly, mGluR5 and
NMDA receptor (NMDAR) co-assemble in the same Homer-
containing PSD complex25, 29. In the presence of Homer1a, the
multimeric mGluR5/Homer complex is disrupted, permitting
direct physical and functional interactions between NMDAR and
mGluR5 and promoting mGluR5-mediated inhibition of
NMDAR currents30, 31.
Here we explored the dynamics of mGluR5 at hippocampal
synapses and the consequences of a disrupted interaction with
Homer proteins for NMDAR function and plasticity, as well as
for related cognitive deﬁcits in Fmr1 KO mice. We addressed this
question using a powerful combination of high-resolution single-
molecule tracking, electrophysiological and knockdown approa-
ches in hippocampal neurons from wild type (WT) and Fmr1 KO
mice, together with behavioral analysis. The majority of these
experiments were performed using the second-generation Fmr1
KO mouse line, which lacks both Fmr1 mRNA and FMRP32.
Certain electrophysiological experiments were performed both in
the second-generation and ﬁrst-generation33 mutants, demon-
strating good comparability between these models. We found that
the lateral mobility of mGluR5 was increased speciﬁcally at the
synaptic sites in Fmr1 KO hippocampal neurons and correlated
with an increased synaptic conﬁnement and co-clustering of
mGluR5 and NMDAR, likely resulting from the mGluR5/Homer
disruption. This led us to investigate changes in synaptic
NMDAR currents and their long-term depression following
mGluR5 activation. These synaptic phenomena were recapitu-
lated in WT neurons by a peptide-based approach that disrupted
the mGluR5/Homer scaffold. Importantly, we found that restor-
ing this mGluR5/Homer interaction by reducing the expression of
Homer1a in the hippocampus rescued abnormal NMDAR func-
tion and plasticity as well as cognitive deﬁcits in Fmr1 KO mice.
Our data highlights the importance of altered mGluR5 dynamics
for the pathophysiology of FXS, corroborating the view that the
regulation of the interaction of mGluR5 with long Homer iso-
forms represents a promising therapeutic target for FXS.
Results
Exaggerated synaptic mobility of mGluR5 in Fmr1 KO neurons.
In spite of its prominent role in the pathophysiology of FXS, the
dynamics of mGluR5 at synapses have not yet been studied in the
context of this disorder. Here we used a single nanoparticle
(quantum dot; QD) imaging approach to track surface mGluR5 in
live hippocampal neurons derived from second-generation Fmr1
KO and WT mouse embryos (12–15 days in vitro). This tech-
nique permitted us to examine the exploratory activity of single-
particle complexes within deﬁned sub-cellular compartments.
Synapses were labeled using an active mitochondria marker
(MitoTracker) to distinguish them from extrasynaptic sites, as
previously described34 (Fig. 1a). MitoTracker labeled synaptic
sites similarly in WT and KO neurons (Supplementary Fig. 1). An
analysis of the trajectories of single mGluR5 molecules revealed
that their diffusion coefﬁcient was signiﬁcantly enhanced within
the synaptic compartment of Fmr1 KO as compared with WT
neurons (Fig. 1b, c; 41.18%; P< 0.001; WT mobility values were
similar to those reported previously23). This result indicates an
increased mobility of mGluR5 within the synaptic membrane of
Fmr1 KO neurons. Accordingly, the fraction of mobile mGluR5
(diffusion coefﬁcient >0.005 μm2/s) at the synapse was higher in
Fmr1 KO neurons (+16.83%; P< 0.001). In contrast to the
synaptic sites, lateral mobility of mGluR5 at extrasynaptic sites
was comparable between Fmr1 KO and WT neurons (Fig. 1d;
diffusion coefﬁcient, P= 0.106; mobile fraction, P= 0.833).
To determine whether the observed increase in membrane
mobility was speciﬁc for mGluR5, or a more general phenomenon
affecting other glutamate receptors as well, we also quantiﬁed the
mobility of individual AMPA-type (AMPAR) and NMDA-type
(NMDAR) glutamate receptors. To this end, we used antibodies
speciﬁc to the extracellular domains of the GluA2 and GluN1
receptor subunits comprising the AMPAR and NMDAR tetramer
complexes, respectively, in conjunction with the same QD
tracking approach. The dynamics of these receptor subunits have
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been extensively characterized previously using QD-based track-
ing approaches34 (see also Supplementary refs.1–4). We found no
differences in the lateral diffusion and the mobile fraction of
AMPAR within the synaptic compartment (diffusion coefﬁcient,
P= 0.732; mobile fraction, P= 0.913), whereas a small but
signiﬁcant reduction was detected in the extrasynaptic compart-
ment (diffusion coefﬁcient: –4.21%, P< 0.001; mobile fraction:
–4.53%, P< 0.001) of Fmr1 KO neurons (Supplementary
Fig. 2a–c). Conversely, NMDAR showed a small yet statistically
signiﬁcant increase in the lateral diffusion both in the synaptic
(diffusion coefﬁcient: +13.33 %, P< 0.001) and the extrasynaptic
sites (diffusion coefﬁcient: +13.60 %, P< 0.001) of Fmr1 KO
neurons, which was not sufﬁcient to affect the fraction of mobile
receptors in both compartments (synaptic sites, P= 0.517;
extrasynaptic sites, P= 0.860; Supplementary Fig. 3a–c). These
data suggest that the absence of FMRP differentially impacts the
mobility of mGluR5, AMPAR and NMDAR, with a major effect
for mGluR5 at synaptic sites.
Impaired mGluR5/Homer scaffold alters mGluR5 diffusion.
Since Homer isoforms function as anchoring molecules for
mGluR5 at synapses25, we hypothesized that the previously
described reduction in mGluR5/Homer interaction17 might lead
to the exaggerated membrane mobility of mGluR5 in Fmr1 KO
neurons reported here. If our prediction was correct, then dis-
rupting the speciﬁc mGluR5/Homer interaction in WT neurons
should mimic the disease phenotype. We tested this hypothesis,
using a cell-permeable peptide containing the Homer binding
motif of mGluR5 (TAT-mGluR5ct; characterized previously35, 36;
Fig. 2a). Indeed, pre-incubation of WT neurons with TAT-
mGluR5ct caused an increase in the lateral diffusion and mobile
fraction of mGluR5 in the synaptic compartment (Fig. 2b–d;
diffusion coefﬁcient: +62.5%; mobile fraction: +12.57%; WT
TAT-mGluR5ct vs. WT TAT-mGluR5mu; P< 0.001 for both
parameters). Importantly, both parameters were now comparable
to those of Fmr1 KO neurons without the peptide (Fig. 2c, d;
diffusion coefﬁcient, P> 0.999; mobile fraction, P= 0.531). As
expected, pre-incubation of WT neurons with a peptide con-
taining a mutated Homer binding motif (TAT-mGluR5mu35, 36)
had no effect on the lateral diffusion of mGluR5 (Fig. 2c, d;
diffusion coefﬁcient, P> 0.999; mobile fraction, P= 0.795).
Moreover, neither TAT-mGluR5ct nor TAT-mGluR5mu treat-
ment had any effect on the mGluR5 mobility in Fmr1 KO neu-
rons (Fig. 2c, d; diffusion coefﬁcient, P= 0.966; mobile fraction, P
= 0.088; Fmr1 KO TAT-mGluR5ct vs. Fmr1 KO TAT-
mGluR5mu). Taken together, these experiments provide strong
correlative evidence that changes in the lateral diffusion of
mGluR5 detected in Fmr1 KO neurons are indeed due to a dis-
rupted link between the long Homer scaffolding proteins and
mGluR5.
Enhanced mGluR5/NMDAR co-clustering in Fmr1 KO neurons.
In addition to anchoring mGluR5 at synapses, Homer-containing
complexes also provide a physical link to NMDARs29. We thus
explored whether the disrupted mGluR5–Homer scaffold might
also alter the interaction between mGluR5 and NMDAR in Fmr1
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Fig. 1 Cell-surface mGluR5 displays an increased lateral diffusion rate within the synaptic compartment of hippocampal Fmr1 KO neurons. (a) Experimental
setup. Upper panel: schematic representation of endogenous mGluR5 in the dendritic membrane labeled with a QD-antibody complex targeting the
extracellular domain of the receptor. Lower panel: representative images of the dendrites of hippocampal neurons shown in phase contrast (left), and their
MitoTracker-labeled synaptic sites (right; green) overlaid with reconstructed trajectories of surface mGluR5-QD complexes (depicted in red) in the
dendritic membrane of the same neurons. Scale bar= 5 μm. (b) Representative trajectories of single surface mGluR5-QD in WT and Fmr1 KO neurons. The
synaptic sites are represented by the green areas. Scale bar= 1 μm. (c) Cumulative distribution (left panel) and cumulative frequency distribution (right
panel) of the instantaneous diffusion coefﬁcient of mGluR5-QDs in the synaptic compartment. The lateral diffusion is signiﬁcantly higher in Fmr1 KO
neurons (WT, 0.017± 0.001 µm2/s, n= 1632 trajectories from 16 dendritic ﬁelds of 3 different cultures); Fmr1 KO, 0.024± 0.001 µm2/s, n= 1451
trajectories (14 dendritic ﬁelds from 3 cultures); ***P< 0.001 by Mann–Whitney test on cumulative distribution; ***P< 0.001 by Kolmogorov–Smirnov test
on cumulative frequency distribution). (d) Cumulative distribution (left panel) and cumulative frequency distribution (right panel) of the instantaneous
diffusion coefﬁcient of mGluR5-QDs in the extrasynaptic area of WT and Fmr1 KO neurons (WT, 0.045± 0.002 µm2/s, n= 1907 trajectories from 16
dendritic ﬁelds of 3 different cultures; Fmr1 KO, 0.048± 0.002 µm2/s, n= 1347 trajectories from 14 dendritic ﬁelds of 3 different cultures; P= 0.106 by
Mann–Whitney test on cumulative distribution; P= 0.649 by Kolmogorov–Smirnov test on cumulative frequency distribution)
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KO neurons. In a ﬁrst set of experiments, we took advantage of
the detection accuracy of single QDs (reviewed in ref. 20) by
measuring the synaptic fraction of mGluR5-QD and GluN1-QD
co-localized with MitoTracker (Fig. 3a). We found that the
synaptic fraction of both mGluR5-QD and GluN1-QD was
increased in Fmr1 KO neurons (Fig. 3b; mGluR5, P< 0.001;
GluN1, P< 0.01). This ﬁnding provides direct evidence that
mGluR5 and NMDAR are more conﬁned within the synapse in
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Fig. 3 mGluR5 and GluN1 are more conﬁned within the synaptic compartment in Fmr1 KO neurons. (a) Representative surface distribution of mGluR5-QD
(upper panel) and GluN1-QD (lower panel) in a 500-frame stack (each dot represents the detection of a single receptor during 50-ms acquisition time),
revealing the synaptic site as a trapping zone (green). (b) Relative fractions of synaptic mGluR5-QD (left panel) and GluN1-QD (right panel) particles.
These values are increased in Fmr1 KO neurons (mGluR5-QD: WT, 8.053± 0.504 %, n= 16 dendritic ﬁelds from 3 cultures; Fmr1 KO, 15.95± 0.685 %, n=
14 dendritic ﬁelds from 3 cultures; ***P< 0.001, t= 9.44, df= 28, unpaired Student’s t-test; GluN1-QD: WT, 8.318± 0.382 %, n= 63 dendritic ﬁelds from 6
cultures; Fmr1 KO, 10.02± 0.446 %, n= 51 dendritic ﬁelds from 6 cultures; **P< 0.01, t= 2.91, df= 112, unpaired Student’s t-test)
a
COOH 
Homer1a 
FXS 
COOH 
Long homer 
Control 
mGluR5 
COOH 
TAT-mGluR5ct
TAT-mGluR5ct
Experimental condition mimicking FXS 
WT       
WT TAT-mGluR5mu 
Fmr1 KO 
Fmr1 KO TAT-
mGluR5ct 
Fmr1 KO TAT-mGluR5mu 
b
WT TAT-mGluR5ct 
d
0.001 0.010 0.100 1
0.6
0.7
0.8
0.9
1.0
Cu
m
ul
. f
ra
ct
io
n
Fmr1 KO TAT-mGluR5mu
Fmr1 KO TAT-mGluR5ct
WT TAT-mGluR5mu
WT TAT-mGluR5ct
***
Syn. diff. coeff. (µm2/s)
WT
WT
 TA
T-m
Glu
R5
mu
WT
 TA
T-m
Glu
R5
ct
Fm
r1 
KO
 
Fm
r1 
KO
 TA
T-m
Glu
R5
mu
Fm
r1 
KO
 TA
T-m
Glu
R5
ct
0
50
100
150
200
N
or
m
al
iz
ed
 s
yn
.
di
ff.
 c
oe
ff.
 (µ
m
2 /s
) (
% 
of 
W
T) ***
NSc
Fig. 2 Disruption of the link between mGluR5 and Homer in WT neurons mimics the Fmr1 KO phenotype. (a) Schematic illustration of the effect of the cell-
permeable TAT-mGluR5ct peptide. This peptide disrupts the mGluR5/Homer link, mimicking the situation in Fmr1 KO neurons. (b) Representative
trajectories of single surface mGluR5-QD in WT and Fmr1 KO neurons treated with TAT-mGluR5ct and its mutated TAT-mGluR5mu control peptide (both
peptides 5 µM, 1 h). The synaptic sites are represented by the green areas. Scale bar= 1 μm. (c) Normalized cumulative distribution of the instantaneous
diffusion coefﬁcient of mGluR5-QDs in the synaptic area of WT and Fmr1 KO neurons treated with TAT-mGluR5mu and TAT-mGluR5ct. The lateral
diffusion rate of mGluR5-QDs in WT neurons treated with TAT-mGluR5ct peptide is comparable to that in Fmr1 KO neurons under basal conditions (WT,
0.016± 0.002 µm2/s, n= 636 trajectories from 12 dendritic ﬁelds of 3 cultures; WT TAT-mGluR5mu, 0.016± 0.002 µm2/s, n= 1798 trajectories from 12
dendritic ﬁelds of 3 cultures; WT TAT-mGluR5ct, 0.026± 0.002 µm2/s, n= 1444 trajectories from 19 dendritic ﬁelds of 3 cultures; Fmr1 KO, 0.025±
0.002 µm2/s, n= 797 trajectories from 16 dendritic ﬁelds of 3 cultures; Fmr1 KO TAT-mGluR5mu, 0.023± 0.001 µm2/s, n= 1419 trajectories from 13
dendritic ﬁelds of 3 cultures; Fmr1 KO TAT-mGluR5ct, 0.024± 0.002 µm2/s, n= 489 trajectories from 9 dendritic ﬁelds of 3 cultures; WT TAT-mGluR5mu
vs. WT TAT-mGluR5ct ***P< 0.001 by Kruskal–Wallis test with Dunn’s multiple comparison test; WT TAT-mGluR5ct vs. Fmr1 KO P> 0.999 by
Kruskal–Wallis test with Dunn’s multiple comparison test). (d) Cumulative frequency distribution of the instantaneous diffusion coefﬁcient of mGluR5-QDs
within the synaptic area of WT and Fmr1 KO neurons treated with TAT-mGluR5mu and TAT-mGluR5ct (***P< 0.001 by Kolmogorov–Smirnov test. For
statistical analysis each condition was separately compared to WT TAT-mGluR5mu)
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Fmr1 KO neurons, likely increasing the probability of physical
interactions between these receptors within a given time window.
To extend these ﬁndings, we performed a triple immuno-
ﬂuorescence labeling experiment for mGluR5, NMDAR and
Homer1 (the latter used as a synaptic marker), together with
confocal microscopy and post hoc image analysis (Fig. 4a–d).
Quantitative analysis of the proportion of mGluR5-/Homer1-
positive or GluN1-/Homer1-positive ﬂuorescence intensity
(expressed as a function of total mGluR5- or GluN1 signal)
suggests an increased localization of both mGluR5 and NMDAR
at the synapse in Fmr1 KO neurons (Fig. 4b, c, respectively;
mGluR5, P< 0.001; NMDAR, P< 0.001). In addition, combined
analysis of all three markers points to a higher degree of
co-clustering of mGluR5 and NMDAR at synaptic sites (Fig. 4d;
P< 0.05) further supporting a tighter association of these
receptors in the absence of FMRP.
To further examine whether the disrupted mGluR5/Homer
scaffold might provide a causal mechanism for this increased co-
clustering of mGluR5 and NMDAR in Fmr1 KO neurons, we
again exploited the interfering peptide. As expected, the pre-
incubation of WT neurons with TAT-mGluR5ct resulted in a
signiﬁcant increase in the mGluR5/NMDAR co-localization
(Fig. 4e; P< 0.05), reﬂecting the increased percentage of synaptic
mGluR5 and NMDAR (Supplementary Fig. 4a–c). Pre-incubation
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Fig. 4 Disruption of the mGluR5/Homer scaffold increases surface mGluR5/NMDAR co-clustering. (a) Cultured WT and Fmr1 KO hippocampal neurons
were triple-labeled for mGluR5, GluN1 and Homer1. (b, c) Left: Representative image of Homer/mGluR5 and Homer/GluN1 co-localization; middle:
Distribution of co-localized mGluR5/Homer1 or GluN-/Homer1 clusters; right: mGluR5/Homer1 and GluN1/Homer1 clusters as percentage of total mGluR5
or GluN1 signal (mGluR5: WT, 9.53± 0.959 %, n= 27; Fmr1 KO, 34.14± 4.598 %, n= 20; ***P< 0.001, t= 6, df= 45, unpaired Student’s t-test; GluN1: WT
15.75± 1.841 %, n= 29; Fmr1 KO 37.15± 5.324 %, n= 18; ***P< 0.001, t= 4.47, df= 45, unpaired Student’s t-test). (d) Left: Representative image showing
mGluR5/GluN1/Homer1 colocalization; middle: Distribution of co-localized mGluR5/GluN1/Homer1 labeling; right: Co-localized mGluR5/GluN1/Homer1
clusters as percentage of synaptic GluN1 signal (WT, 63.97± 2.414 %, n= 26; Fmr1 KO, 72.14± 2.081 %, n= 23; *P< 0.05, t= 2.53, df= 47, unpaired
Student’s t-test). (e) TAT-mGluR5ct peptide increased mGluR5/GluN1 co-clustering at synapses in WT neurons, whereas TAT-mGluR5mu or TAT-
mGluR5ct (both 5 µM, 1 h) had no effect in Fmr1 KO neurons; Left: Representative images and distribution of mGluR5/GluN1/Homer1-co-labeling signal in
control and TAT-mGluR5mu or TAT-mGluR5ct treated WT and Fmr1 KO neurons. Right: Co-localized mGluR5/GluN1/Homer1-positive signals as
percentage of synaptic GluN1 signal (WT: 63.97± 2.414 %, n= 26; WT TAT-mGluR5mu: 61.19± 3.489 %, n= 14; WT TAT-mGluR5ct: 71.79± 1.528 %,
n= 22; WT vs. WT TAT-mGluR5ct, *P= 0.043; WT TAT-mGluR5mu vs. WT TAT-mGluR5ct *P= 0.017, F (2, 59)= 4.87; Fmr1 KO: 72.14± 2.081 %,
n= 23; Fmr1 KO TAT-mGluR5mu: 67.32± 2.832 %, n= 18; Fmr1 KO TAT-mGluR5ct: 67.58± 2.69 %, n= 26; Fmr1 KO vs. Fmr1 KO TAT-mGluR5ct
P= 0.391; Fmr1 KO TAT-mGluR5mu vs. Fmr1 KO TAT-mGluR5ct P= 0.997, F (2, 64)= 1.13). P values by one-way ANOVA test with Tukey’s Multiple
Comparison test. n= dendritic ﬁelds from 3 cultures. Scale bar= 10 μm (a) 2 μm (b, c, d, e)
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with TAT-mGluR5mu had no effect on the co-localization
(Fig. 4e; P= 0.725; Supplementary Fig. 4a–c). Thus, the
disruption of the mGluR5/Homer binding is likely responsible
for a tighter physical association between mGluR5 and NMDAR
at synapses in Fmr1 KO neurons.
Reduced NMDAR function and plasticity in Fmr1 KO neurons.
What are the consequences of this tighter mGluR5/NMDAR
association at synaptic sites for NMDAR function? To address
this question, we measured synaptic NMDAR-mediated excita-
tory postsynaptic currents (EPSCsNMDA) induced by Schaffer
collateral stimulation using whole-cell patch-clamp recordings
from CA1 pyramidal neurons in acute hippocampal slices
(Fig. 5a). EPSCsNMDA displayed lower amplitudes in Fmr1 KO
neurons when compared with WT neurons (Fig. 5b; Fmr1 KO:
46.4± 8.4 pA; WT: 175.7± 21.9 pA; P< 0.001). Consistently, the
NMDA/AMPA ratio was signiﬁcantly lower in Fmr1 KO neurons
(Fig. 5c; Fmr1 KO: 0.86± 0.05; WT: 1.37± 0.29; P= 0.02). These
defects in NMDAR function were mimicked in WT neurons by
application of the interfering peptide TAT-mGluR5ct (Fig. 5b;
EPSCsNMDA, TAT-mGluR5ct: 88.01± 12.70 pA; P< 0.01 com-
pared to untreated WT; Fig. 5c; NMDA/AMPA ratio, TAT-
mGluR5ct: 0.88± 0.10; P= 0.02 compared to untreated WT).
These data thus strongly support our hypothesis that alterations
in the membrane dynamics of mGluR5, and its tighter coupling
with NMDAR—in the synapses of both Fmr1 KO neurons as well
as in neurons treated with the disrupting peptide—contribute to
abnormal NMDAR function.
It is well established that the activation of group-I mGluR
induces an exaggerated LTD of excitatory postsynaptic AMPA
currents (EPSCAMPA) in hippocampal Fmr1 KO neurons13. In
contrast, LTD of excitatory postsynaptic NMDA currents
(EPSCsNMDA) mediated by group-I mGluR activation37–39 has
not been investigated in Fmr1 KO mice. In WT hippocampal
CA1 neurons, application of the group-I mGluR orthosteric
agonist (S)-3,5-dihydroxyphenylglycine (DHPG, 100 µM, 5min)
induced a strong and long-lasting reduction in EPSCsNMDA
(Fig. 5d). Remarkably, this form of synaptic NMDAR plasticity
was largely absent in Fmr1 KO neurons (Fig. 5d; P= 0.0006). As
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Fig. 5 Disruption of mGluR5/Homer coupling alters synaptic NMDAR function and plasticity. (a) NMDAR-mediated excitatory post-synaptic currents
(EPSCsNMDA) were recorded from CA1 pyramidal neurons. Scale bar = 100 μm (b) Left: representative EPSCsNMDA traces from WT, Fmr1 KO, WT treated
with either TAT-mGluR5ct or TAT-mGluR5mu (both 5 µM, 4 h). Histograms: EPSCsNMDA amplitude (F(3, 35)= 6.26; **P= 0.0016; one-way ANOVA with
Tukey’s Multiple Comparison). Compared to WT (175.7± 21.9 pA, n= 11 neurons from 7 animals), EPSCsNMDA were lower in Fmr1 KO (46.4± 8.4 pA, n=
7 neurons from 4 animals, **P< 0.01) and in WT treated with TAT-mGluR5ct (88.1± 12.7 pA, n= 13 neurons from 7 animals, *P< 0.05) but not with
TAT-mGluR5mu (125.9± 16.8 pA n= 8 neurons from 3 animals, P= 0.14). (c) NMDA/AMPA ratio in WT, Fmr1 KO, WT treated with TAT-mGluR5ct or
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9 neurons from 3 animals, *P= 0.02). (d, f) The mGluR1/5 agonist DHPG (100 µM, 5min) induced long-term depression (mGluR-LTD) of EPSCsNMDA in
WT (EPSCsNMDA amplitude: 24.9± 2 % of baseline, n= 8 neurons from 5 animals) but not in Fmr1 KO (EPSCsNMDA 107.8± 25 %, n= 6 neurons from 4
animals, **P< 0.01, WT vs. Fmr1 KO). (e, f) mGluR-LTD of EPSCsNMDA was abolished in WT treated with TAT-mGluR5ct (EPSCsNMDA 100.6± 15 %, n= 8
neurons from 7 animals, **P < 0.01, WT vs. TAT-mGluR5ct) but not with TAT-mGluR5mu (EPSCsNMDA 56.6± 11 %, n= 7 neurons from 3 animals). (f)
mGluR-LTD magnitude in all conditions (F(3, 19)= 7.27, **P= 0.0019, one-way ANOVA with Tukey’s Multiple Comparison)
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with the enhanced mGluR5/NMDAR co-clustering, this pheno-
type was also recapitulated in WT neurons by use of the peptide
mimicking approach, suggesting the defective mGluR5/Homer
interaction as the underlying cause (Fig. 5e, f; P< 0.01). As
expected, in Fmr1 KO slices pre-treated with TAT-mGluR5ct,
mGluR-LTD of EPSCsNMDA was still largely absent (Fmr1 KO
TAT-mGluR5ct vs. WT, P= 0.032), and comparable to untreated
Fmr1 KO slices (Supplementary Fig. 5a, b; P= 0.69). These data
suggest that the disruption of the mGluR5/Homer scaffold
compromises NMDAR function under both basal conditions, as
well as during synaptic plasticity, in Fmr1 KO neurons.
Homer1a knockdown rescues NMDAR function and plasticity.
Homer1a is known to antagonize the interaction between
mGluR5 and Homer. Thus, we asked whether knocking down
Homer1a—an approach that fosters the mGluR5/Homer inter-
action by decreasing the Homer1a/Homer balance18—could
correct the dysfunction in NMDAR currents in Fmr1 KO neu-
rons. To address this question we exploited an AAV vector
expressing a small interfering hairpin RNA (shRNA) targeted
against the unique 3’-untranslated region of Homer1a mRNA and
GFP bicistronically40, 41. A similar vector expressing scrambled
shRNA and GFP served as control40, 41. AAV vectors were ste-
reotaxically injected into the hippocampal CA1 area of Fmr1 KO
mice and EPSCsNMDA were measured from infected (i.e., GFP
expressing) CA1 pyramidal neurons in acute brain slices 4 weeks
later when transgene protein expression had peaked and
remained at stable levels (Fig. 6a). EPSCsNMDA displayed higher
amplitudes in Fmr1 KO neurons expressing the shRNA targeted
against Homer1a when compared to Fmr1 KO neurons expres-
sing the scrambled shRNA (Fig. 6b; P< 0.05). In addition, the
mGluR-dependent LTD of EPSCsNMDA, that was absent in Fmr1
KO neurons, was restored in Fmr1 KO neurons expressing the
shRNA for Homer1a (Fig. 6c; P< 0.001). Both ﬁndings conﬁrm
our hypothesis that mGluR5/Homer disruption can cause
abnormal NMDAR function and plasticity in Fmr1 KO neurons.
Homer1a knockdown rescues cognitive defects in Fmr1 KO
mice. Can the correction of the disrupted mGluR5/Homer scaf-
fold also rescue cognitive defects linked to NMDAR dysfunction?
To evaluate the effects of Homer1a reduction on hippocampus
dependent memory formation, we used two behavioral tasks—a
one-trial acquisition novel object-recognition task (NOR), per-
formed on an L-maze and which tests episodic memory42, and
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ANOVA test with Tukey’s test)
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contextual fear conditioning (CFC)43. Both procedures induce
robust hippocampus dependent learning with a single training
episode, and have previously been utilized for the investigation of
memory defects in the Fmr1tm1Cgrmouse42, 43. Since these phe-
notypes have not previously been investigated in the second-
generation Fmr1 KO mouse model, we initially performed a pilot
experiment with a separate batch of experimentally naïve animals
to determine whether we could recapitulate these phenotypes.
Consistent with the aforementioned studies employing the ﬁrst-
generation Fmr1 KO mouse line, the second-generation model,
used here, exhibited similar decreases in the discrimination index
(DI) in the NOR task (Supplementary Fig. 6, Fig. 7, Fig. 8 and
Fig. 9; P< 0.001) and in the percentage of freezing compared with
WT mice following retrieval of CFC memory (Supplementary
Fig. 10; P< 0.001). We then tested whether mGluR5/Homer
crosstalk modulation could correct these defects in another batch
of behaviorally naive Fmr1 KO mice, stereotaxically injected with
the aforementioned AAV vectors into the CA1 area of the hip-
pocampus. Importantly, the selective Homer1a knockdown in the
hippocampus (Fig. 6a) corrected defects in both the NOR
memory (Fig. 6d; Fmr1 KO AAV-sh H1a vs. Fmr1 KO AAV-scr,
P< 0.001; Supplementary Fig. 11, Fig. 12, Fig. 13 and Fig. 14) and
CFC memory (Fig. 6e; Fmr1 KO AAV-sh H1a vs. Fmr1 KO
AAV-scr, P< 0.01) in adult Fmr1 KO mice. Taken together with
the aforementioned results, these data strongly support the idea
that disruption of mGluR5/Homer scaffold, leading to altered
NMDAR function in the hippocampus contributes to impairment
of hippocampal-dependent cognitive function in Fmr1 KO mice.
Discussion
In spite of the widespread acceptance of the mGluR theory of
FXS, the sub-cellular mechanisms underlying mGluR5-dependent
defects in synaptic function and plasticity, as well as their asso-
ciated cognitive phenotypes remain poorly understood. Most
studies, to date, have focused on the altered translational pro-
cesses arising from perturbations in mGluR signaling and their
ensuing effect on synaptic plasticity. Surprisingly scant attention,
however, has been paid to the behavior of the receptor itself and
its interactions with other membrane-bound receptors. Here we
present several novel aspects of mGluR5 pathophysiology in FXS.
Speciﬁcally, we show that not only are the dynamics of mGluR5
altered at the synapse of Fmr1 KO neurons (leading to a greater
lateral diffusion of the receptor), but also that the conﬁnement of
the receptor at the synapse is increased. These changes are
accompanied by an enhanced co-clustering of mGluR5 and
NMDAR at synapses as well as altered NMDAR function/plas-
ticity in the hippocampal CA1 region of Fmr1 KO mice.
Importantly, our experiments point to a plasticity defect not
previously reported involving mGluR5-mediated LTD of NMDA
receptor currents in FXS. This NMDAR dysfunction and lack of
plasticity correlates with hippocampus dependent cognitive
deﬁcits.
Previous studies have shown that interactions between
mGluR5 and postsynaptic density scaffolding proteins, in parti-
cular Homer, are critical for the correct functioning of mGluR5
(reviewed in ref. 26). Conversely, disruption of this
mGluR5–Homer association in the absence of FMRP17 has been
reported to play a key causal role in several FXS phenotypes such
as anxiety, susceptibility to seizures and changes in circuit level
hyperexcitability in the neocortex and hippocampus18, 19, 44. To
explore whether alterations in mGluR5–Homer crosstalk might
contribute to the changes in mGluR5 mobility and NMDAR
function reported here, we made use of a peptide disruption
approach35 to perturb the normal interactions between mGluR5
and long Homer isoforms. Indeed, we found that application of
this peptide recapitulated changes in mGluR5 mobility detected
in Fmr1 KO mice. This ﬁnding was in coherence with previous
studies demonstrating that interaction of mGluR5 with Homer
proteins at the postsynaptic site regulates lateral diffusion of
mGluR545. The fact that the exaggerated mGluR5 mobility is
restricted to the synapse is not surprising taking into considera-
tion that long Homer isoforms are enriched at synaptic sites28.
Interestingly, these alterations in receptor dynamics appear to be
speciﬁc to the mGluR5–Homer interaction because the AMPAR
subunit, GluA2, which does not bind Homer proteins, did not
exhibit substantial alterations in lateral diffusion in the synaptic
area. Noteworthy, although these mobility values may be inﬂu-
enced by a number of experimental variables, our measures for
WT neurons are consistent with those reported under similar
conditions (e.g., ref. 23; see also Supplementary Table 1). In
addition to alterations in mGluR5 mobility, we also found that
application of the peptide led to an increased synaptic conﬁne-
ment of mGluR5, the co-clustering of mGluR5 and NMDAR, and
ultimately, to alterations in NMDAR function and NMDAR-
dependent plasticity—features that we also observed in Fmr1 KO
neurons. Taken together, these ﬁndings suggest a strong causative
role for the altered mGluR5–Homer crosstalk in the aforemen-
tioned novel changes in mGluR5 dynamics and NMDAR func-
tion in FXS (see model in Fig. 7).
Although alterations in synaptic plasticity have been well
documented in FXS, this is the ﬁrst report of a defect in mGluR5-
mediated LTD of NMDAR-mediated EPSCs in Fmr1 KO mice.
This is surprising, given that this form of plasticity is well char-
acterized in non-disease models (e.g. refs. 37–39). Our results
suggest that a disruption of the link between mGluR5 and Homer
proteins in Fmr1 KO neurons plays a negative role in the
induction of LTD of synaptic EPSCsNMDA in response to group-I
mGluR activation. In this scenario, mGluR5 once liberated from a
co-assembly with Homer1 partners would undergo an increased
NMDAR
dysfunction and
cognitive defects
Long Homer 
mGluR5 
Control 
NMDAR 
Shank
GKAP 
PSD-95 
Lateral
diffusion
Homer1a 
FXS 
Fig. 7Model for dysfunction of the NMDAR/mGluR5 crosstalk in Fmr1 KO neurons. In WT neurons, long Homer proteins anchor mGluR5 to a chain of PSD
proteins in the synapse and prevent a direct interaction with NMDAR. Under those conditions, a co-clustering of mGluR5 and NMDAR is prevented. In Fmr1
KO neurons, mGluR5 is less associated with the long Homer proteins and more associated with the short isoform, Homer1a. This disengagement from the
long Homer protein–containing complex increases the lateral diffusion of mGluR5 and promotes its interaction with synaptic NMDAR. This conﬁguration at
the synapse prevents boosting of NMDAR currents under control conditions and their LTD following mGluR5 stimulation
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physical and functional interaction with NMDAR, altering the
function of this receptor type31. In line with previous results, we
found that EPSCsNMDA evoked by Schaffer collateral stimulation
showed lower amplitudes in Fmr1 KO neurons. The altered
mGluR5/NMDAR partnership might also impact on NMDAR
removal from the synapse, a mechanism that is believed to be
responsible for depression of synaptic NMDAR currents38. In
support of this notion, we found that NMDAR is more conﬁned
at synapses in the Fmr1 KO neurons (and in WT neurons fol-
lowing incubation with the TAT-mGluR5ct peptide). One pos-
sible mechanism for the inhibition of NMDAR currents might be
a direct interaction of NMDAR with G-protein βγ subunits30—
facilitated by the physical constraint between mGluR5 and
NMDA. Similarly, steric hindrance caused by a closer association
between NMDAR and mGluR5 could prevent post-translational
modiﬁcation of NMDAR, underlying their removal from synap-
ses. Whereas the induction of group-I mGluR mediated LTD of
AMPA currents involves both pre- and post-synaptic mechan-
isms46–48, we suggest that the group-I mGluR mediated LTD of
NMDA currents reported here engages a post-synaptic mechan-
ism. This conclusion is based on the post-synaptic location of
Homer proteins, and also supported by previous studies into the
mechanism of this plasticity form37.
How might the absence of FMRP cause mGluR5/Homer dis-
ruption and consequently the described changes in mGluR5 and
NMDAR function? The increased phosphorylation of Homer has
previously been demonstrated to reduce its afﬁnity for mGluR549.
On the other hand, the increased phosphorylation of mGluR5
induces a higher afﬁnity for Homer50. This would provoke a
remodeling of mGluR5–Homer-NMDAR complexes, freeing
mGluR5 to form functional associations with NMDAR and
potentially leading to the observations reported here. Although
this provides a tantalizing explanation for our ﬁndings, it may not
be the only mechanism underlying these changes. Moreover,
given that the loss of FMRP leads to the dysregulated translation
of a plethora of target mRNAs it is difﬁcult to pinpoint one kinase
as the causative factor. While inhibition of CaMKII in acute slices
and cultured neurons from Fmr1 KO mice has been shown to
correct aberrant UP states and frequency of spontaneous ﬁring—
features that are indicative of altered circuit level activity49—it is
conversely possible that altered circuit function can impinge on
mGluR5–Homer crosstalk. Altered circuit level activity has been
well documented in Fmr1 KO mice (e.g. refs. 51, 52) and may play
a role in a number of central phenotypes of the disorder53.
Increased circuit activity can be expected to inﬂuence immediate
early gene induction27, 28, leading to increased Homer1a
expression, which exacerbates crosstalk disruption. This disrup-
tion, in turn, may drive further alterations in circuit level func-
tion49. Interestingly, our experiments involving hippocampal
speciﬁc knockdown of Homer1a suggest discrete and indepen-
dent mechanisms for Homer1a in the pathology of FXS. In par-
ticular, we show here that hippocampal-dependent defects occur
through functional modiﬁcation of NMDAR. Altered mGluR-
dependent NMDAR-LTD might be expected to profoundly
impact cognitive functions in FXS. In support of this notion, the
plasticity of NMDAR currents has recently been suggested to
provide a mechanism for metaplasticity39, 54. In addition,
hippocampal-dependent cognitive impairment induced by social
defeat stress has been linked to a reduced Homer-mGluR5
interaction in mice55. Likewise, a selective over-expression of
Homer1a in the dorsal hippocampus has been shown to impair
spatial working memory56.
Here we show the rescue of two hippocampus- and NMDAR-
dependent cognitive phenotypes by knockdown of Homer1a
expression speciﬁcally in the hippocampus. Although previous
work has shown that generalized genetic ablation of Homer1a
rescued certain behavioral phenotypes of Fmr1 KO mice related
to anxiety and seizure susceptibility18, these tests have no direct
correspondence with cognitive performance, which is one of the
prevailing features of FXS. Here we demonstrate rescue of two
phenotypes with direct relevance to cognitive function. Moreover,
we demonstrated that knockdown within the hippocampus alone
is sufﬁcient to rescue these phenotypes. In addition, rescue of
cognitive function was correlated with rescue of a novel synaptic
plasticity defect. We are aware that recent literature has raised
concerns about the robustness of the cognitive phenotypes
reported in the Fmr1 KO model (reviewed in refs. 57, 58). It is thus
imperative to establish robust tests that can be replicated between
laboratories to strengthen the use of the Fmr1 KO mouse as a
preclinical model of FXS57. To this end, the use of the non-
classical object–recognition test (performed on an L-maze)42, 59,
and of a purely contextual fear memory paradigm43 rather than
auditory fear conditioning (that has typically been used for the
Fmr1 KO model e.g. refs. 60–63) may represent an important
reﬁnement for cognitive testing of the Fmr1 KO mouse. Our
study, using the second-generation model, replicates ﬁndings
reported for the ﬁrst-generation Fmr1tm1Cgr model, suggesting
that these tests are robust and reproducible between independent
laboratories. With respect to contextual fear memory, the key
difference between our work (and the ﬁndings of refs. 43, 64) and
previous ﬁndings in the ﬁeld is that we paired the shock with the
presentation of the context. This paradigm leads to a different
relevance of the background vs. foreground sensorial cues and the
related recruitment of the hippocampus, compared with the
protocol used for auditory fear conditioning. This task could thus
be more suitable for the detection of behavioral deﬁcits in the
Fmr1 KO mice.
These ﬁnding can be expected to have wider implications for
future therapeutic approaches for the treatment of FXS and other
neurodevelopmental disorders. NMDAR hypofunction has been
detected in FXS models in other brain regions and has been
recently proposed to contribute to cognitive defects in FXS
(reviewed in ref. 65). In addition, it has been considered sig-
niﬁcant in the context of autism and schizophrenia and its cor-
rection by means of mGluR5-positive allosteric modulators has
been proposed66. Indeed, mice with reduced expression of the
NMDAR subunit, GluN1 exhibit a range of behavioral pheno-
types that are not only consistent with autism spectrum disorder,
but also which overlap with those observed in Fmr1 KO mice.
Given the known reciprocal modulation of mGluR5 and NMDA
responses, our results of an altered crosstalk of these two recep-
tors in FXS should be taken into consideration when predicting
the outcome of single or combined therapy with agents targeting
both receptors. Our ﬁnding may also contribute to an improved
understanding of several factors impeding clinical trial design,
such as the marked heterogeneity present within the FXS popu-
lation67. If increased circuit activity (as discussed above) indeed
leads to altered Homer1a levels, then this is likely to vary widely
amongst individuals based on their responses to external stimuli,
environment, etc. Here we propose that therapeutic approaches
aimed at restoring the normal mGluR5/Homer and mGluR5/
NMDAR interactions might provide a promising alternative for
the treatment of FXS. It is hoped that these ﬁndings will con-
tribute to the development of alternative, targeted therapies for
this disorder and its co-morbidities, and provide mechanistic
links to other genetic causes of autism.
Methods
Animals. All experiments were conducted in strict compliance with the European
Directive (2010/63/EU), and French and Italian law governing the use of laboratory
animals and were approved by the Bordeaux Ethics Committee (C2EA50,
authorization #5012024-A) and by the Ethics Committee of Catania University
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(project # 181). Mice were housed in a SPF animal facility prior to experiments,
kept on a 12 h–12 h light–dark cycle (lights on at 0:700 am) and had ad libitum
access to food and water at all times. Second generation Fmr1 KO mice32 were
mostly used in our study. This model was generated by deletion of both the
promoter and exon 1 of the Fmr1 gene, as described previously32. These mice are
distinct from the original Fmr1 KO (Fmr1tm1Cgr) mouse line33, because they are
deﬁcient for both Fmr1 mRNA and FMRP protein. This mouse model has largely
been used for physiological, molecular, and anatomical studies (e.g., ref. 53, see also
Supplementary refs. 5–10), however limited behavioral characterization has also
been performed (e.g., ref. 60 and Supplementary refs. 11–14). Mice were backcrossed
six generations into a C57BL/6 J (Charles River, L’Abresle, France) background and
maintained in this mixed background for all experiments. The genotype of all
progenitors, as well as experimental subjects, was determined by tail PCR as
described previously32). For dissociated neuronal cultures WT and Fmr1 KO
embryos were generated by crossing homozygous (Fmr1+/+ X Fmr1+/y or Fmr1−/−
X Fmr1−/y) progenitor mice. The genotype of the embryos was conﬁrmed by tail
PCR of the mother. For electrophysiology and behavioral experiments male WT
and Fmr1 KO littermates were generated by crossing a heterozygous (Fmr1+/−)
female mouse with a wild-type (Fmr1+/y) male mouse as described previously53.
Mice were subsequently re-genotyped after the experiment by tail PCR as described
previously53. Some electrophysiology experiments (see Fig. 5) were carried out on
ﬁrst-generation (Fmr1tm1Cgr) Fmr1 KO mice (on an FVB background)33. Genotype
was assessed by tail PCR as described previously68.
Primary cell cultures. Cultures of hippocampal neurons and glial cells were
prepared from E18 WT and Fmr1 KO embryos. Pregnant mice were killed by
decapitation after deep anesthesia with isoﬂurane and the uterine horn dissected.
Hippocampi were subsequently dissected from the embryos in ice-cold dissection
solution and then dissociated in trypsin (Sigma, 0.25%). Brieﬂy, cells were plated at
a density of 100 to 200 × 103 cells per milliliter on poly-L-lysine (Sigma) precoated
coverslips and kept at 37 °C in 5% CO2. The original plating Neurobasal culture
medium (Gibco) supplemented with B27 (Gibco, 2%) and complemented with 5%
fetal bovine serum was replaced with a serum free medium on day in vitro (DIV) 2.
Cytosine B-D-arabinofuranoside (Sigma, 5 μM) was added on DIV 4. All the
experiments were performed at DIV 12/15.
Pharmacological treatments. A cell-permeable (TAT-fused) peptide containing
the proline-rich motif (PPXXF) of the mGluR5 C-terminal tail that binds the
EVH1 domain of Homer, TAT-mGluR5ct (YGRKKRRQRRR-ALTPPSPFR), and a
control peptide with a mutated Homer binding motif, mGluR5mu
(YGRKKRRQRRR-ALTPLSPRR), were synthesized at the UT Southwestern Pro-
tein Chemistry Technology Center and kindly provided by Prof. K. Huber
(Department of Neuroscience, University of Texas Southwestern Medical Center,
Dallas, TX 75390, USA; see ref. 35, 36). The peptides were dissolved in H20 at a
concentration of 5 mM, and aliquots of this stock concentration were stored at
−20 °C. Frozen aliquots of both TAT-fused peptides were used within 10 days and
diluted to the desired ﬁnal concentration. Hippocampal cultures were treated with
TAT-mGluR5ct or TAT-mGluR5mu for 1 h at a ﬁnal concentration of 5 µM in
serum free culture medium at 37 °C. Slices were incubated during 4 h with either
TAT-mGluR5ct or TAT-mGluR5mu (each at 5 µM) in oxygenated ACSF at room
temperature (21–22 °C). (S)-3,5-Dihydroxyphenylglycine (DHPG) (Abcam, #
ab120007, 100 µM) was dissolved in ACSF and applied by bath perfusion.
Single-Particle Tracking and Surface Diffusion Calculation. For single-molecule
tracking experiments, neurons were ﬁrst exposed for 10 min to either mouse
monoclonal anti-NH2 mGluR5 antibody (1:20)69, mouse monoclonal anti-GluA2
AMPA receptor (AMPAR) subunit antibody (Millipore, #MAB397, 1:200), or
rabbit polyclonal anti-GluN1 NMDA receptor (NMDAR) subunit antibody
(Alomone Laboratories, #AGC-001, 1 : 20034 and Supplementary refs. 15–19) at
37 °C. Neurons were then incubated for 10 min in a solution containing quantum
dots (QD) 655 coupled to goat anti-mouse IgG (Invitrogen, #Q11022MP) or
coupled to goat anti-rabbit IgG (Invitrogen, #Q-11421MP) (ﬁnal dilution 1:5000/
1 : 10,000) at 37 °C. To label synaptic sites, neurons were incubated for 40 s at RT
(~ 22 °C) in a solution containing the orange mitochondria marker MitoTracker
(Invitrogen, #M-7510, 20 nM). A fraction of coverslips was also incubated for 1 h
with TAT-mGluR5ct or TAT-mGluR5mu (5 µM) in culture medium at 37 °C
before and during the incubation with the primary antibodies. For QD 655
ﬂuorescence imaging we used an EM-CCD camera (Evolve 512, Photometrics)
with a 512 × 512 imaging array together with an HXP-120 light source (Zeiss) and
the appropriate ﬁlters for excitation and emission. Images were acquired at an
integration time of 50 milliseconds for up to 500 consecutive frames (24 s) as
described previously (Supplementary refs. 15,18). QD movements were followed on
randomly selected healthy looking dendritic regions for up to 20 min, and analyzed
using Metamorph software (Universal Imaging Corporation, PA, USA). Brieﬂy, the
instantaneous diffusion coefﬁcient, D, was calculated for each trajectory, from
linear ﬁts of the ﬁrst 4 points of the mean-square-displacement vs. time function
using the following equation: MSD (t)= < r2 > (t) = 4Dt. To assign synaptic
localization, trajectories were sorted into extrasynaptic (i.e. MitoTracker-negative
pixels) and synaptic regions (MitoTracker-positive pixels). To determine the
distribution and synaptic fraction of single QD complexes, frame stacks were
obtained, and on each frame the receptor/QD complexes were precisely located in
synaptic and extrasynaptic compartments. Then, those locations were projected on
a single image, providing a high-resolution distribution of the receptor/QD
complexes.
Immunocytochemistry and confocal analysis. The surface expression of mGluR5
was studied using an antibody against the NH2 terminal of the mGluR5 in non-
permeabilized neurons (see above QD tracking experiments). After removing the
medium, cell cultures were incubated with the antibody (1:10) for 30 min at 37 °C.
Subsequently, cultures were ﬁxed with a solution containing 4% paraformaldehyde
(PFA) and 4% sucrose for 10 min at RT, permeabilized in PBS containing 0.1%
Triton-X for 10 min, incubated with blocking solution containing 4% BSA for 45
min at RT, followed by incubation with the rabbit monoclonal anti-GluN1- NH2
antibody (Alomone Labs, #AGC-001, 1:200) and the Guinea pig polyclonal anti-
Homer1 antibody (Synaptic Systems, #160 004, 1:500) for 1 h at RT. After washing,
cultures were incubated for 45 min at RT with the appropriate secondary ﬂuor-
escent antibodies (Alexa Fluor 647 anti-mouse, Invitrogen, #A-21236, 1:750; Alexa
Fluor 555 anti-rabbit, Invitrogen, #A-21428, 1:750; Alexa Fluor 488 anti-Guinea
pig, Invitrogen, #A-11073, 1:750). Some coverslips were also incubated for 1 h with
TAT-mGluR5ct or TAT-mGluR5mu (ﬁnal concentration for each: 5 µM in culture
medium) at 37 °C before the incubation with anti-mGluR5 antibodies. For
immunohistochemistry on ﬁxed brain tissue for the evaluation of transduction
efﬁciency, free-ﬂoating 50 µm slices were permeabilized in blocking solution (3%
BSA, 10 % normal goat serum in 1× PBS) containing 0.5% Triton-X for 90 min,
then incubated overnight with anti-NeuN (Millipore, clone 60, #MAB377). After
washing, slices were incubated for 2 h at RT with Alexa Fluor 594-conjugated goat
anti-mouse, Invitrogen, #A-11032, 1 : 500) and counter-stained with DAPI.
Images were acquired to measure co-localization of mGluR5, GluN1 and
Homer1, using a commercial Leica DMI6000 TCS SP5 confocal microscope with
identical settings for all conditions. Ten individual confocal images per coverslip
were acquired at 12-bit depth with a pixel size of 96.2 × 96.2 nm (×63 objective,
1.4 NA, 2.5 digital zoom, 1024 × 1024 pixel per image, 50 Hz scanning speed,
98.41 × 98.41 µm ﬁeld of view). Images were processed with AutoquantX software
(MediaCybernetics) and ImageJ software. A minimum of eight randomly chosen
cells per condition was acquired and analyzed. A 2D blind deconvolution algorithm
was ﬁrst applied to each image in order to retrieve better data from our images.
Then, analysis of the co-localization of mGluR5, GluN1 and Homer1 was
performed using the “Co-localization” module of ImageJ (version 1.49; Scion
Image, Frederick, MD). A custom-made macro was used to analyze the dendritic
part of each image by measuring the ﬂuorescence intensity of each label using ﬁxed
threshold intensities.
For the analysis of the ability of the colocalization of MitoTracker and synapses
in WT and Fmr1 KO neurons, cultures (12–15 DIV) were incubated with
MitoTracker (Invitrogen, #M-7510, 20 nM) for 40 min at 37 °C and ﬁxed with 3.7%
PFA for 10 min. Then, cultures were permeabilized in PBS containing 0.2% Triton-
X for 10 min, and incubated with a blocking solution containing 4% BSA and 0.2%
Triton-X for 20 min. Next, cultures were incubated for 90 min at RT with the
following primary antibodies: Guinea pig polyclonal anti-Homer antibody
(Synaptic System, #160 004, 1 : 500) or mouse monoclonal anti-PSD 95
(Thermoscientiﬁc # MA1-046, 1:750); rabbit polyclonal anti-Bassoon antibody
(Synaptic System #141 003, 1 : 1000); after washing, cultures were incubated for 45
min with the secondary ﬂuorescent antibodies: Biotin-SB-conjugated afﬁnity pure
donkey anti-guinea pig (Jackson Immunoresearch, #706-065-148, 1:250) and Cy5
conjugated afﬁnity pure goat anti-rabbit (Jackson Immunoresearch, #111-175-
144, 1:500), or Cy5 conjugated afﬁnity pure goat anti-mouse (Jackson
Immunoresearch, #115-175-146, 1:500) and Alexa Fluor 488-conjugated afﬁnity
pure goat anti-rabbit (Jackson Immunoresearch, #111-545-144, 1:500). Cultures
incubated with the anti-Homer antibody were then incubated for 30 min with
Fluorescein Streptavidin (Vector #SA-5001, 1:250). Images were acquired using
either a LSM-510 Meta confocal microscope (Zeiss) or Leica DMI6000 TCS SP5
and respecting Nyquist sampling parameters (voxel size: 75.2× 75.2× 209 nm; using
63 × 1.4 NA oil DIC, 1.6× digital zoom, 2048 × 2048 pixel size per image, 12 bit
depth, 154 × 154 µm ﬁeld of view and 100 Hz scanning speed). To establish
acquisition parameters, a negative control (without primary antibodies) was used
and images from WT and Fmr1 KO were acquired using identical settings. Images
were then thresholded and analysis of colocalization of MitoTracker-positive
puncta with synapses was performed on randomly selected dendrites using the
“Colocalization module” of ImageJ software in two steps. First, the synapses were
identiﬁed by the colocalization of the post-synaptic markers Homer or PSD-95
with the pre- synaptic marker Bassoon, and then the colocalization between
synapses and MitoTracker was calculated.
Production of recombinant adeno-associated virus. Homer1a mRNA was tar-
geted by RNA interference-mediated silencing. The recombinant adeno-associated
viruses (AAVs) were composed of biscistronic expression of short hairpin RNA,
driven by the mouse RNA polymerase III U6 promoter (oligonucleotides corre-
sponding to Homer1a-speciﬁc shRNA (shH1a; sense strand, 5′-GGAGCAUUGA
GCUAAUUAUTT-3′; antisense strand, 5′-AUAAUUAGCUCAAUGCUCCTT-3′;
Sigma Genosyses), and of control shRNA (sense strand, 5′-GUACUGCUUA
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01191-2
10 NATURE COMMUNICATIONS |8:  1103 |DOI: 10.1038/s41467-017-01191-2 |www.nature.com/naturecommunications
CGAUACGGTT-3′; antisense strand, 5′-CCGUAUCGUAAGCAGUACUTT-3′),
combined with GFP, expressed under the control of the CBA promoter (Supple-
mentary Fig. 15). The entire cassette was ﬂanked by AAV2 inverted terminal
repeats (ITRs). Brieﬂy, rAAV2/1 vectors (shCtrl and shH1a) were produced by
polyethylenimine (PEI)-mediated triple transfection of HEK 293 cells. HEK 293
cells were cotransfected with the AAV cis plasmid (pAAV-U6-shRNA-CBA-GFP-
WPRE-bGH, control shRNA or Homer1a-speciﬁc shRNA40, 41, the AAV1 (pH21)
and AAV2 (pRV1) helper plasmids, and the adenovirus helper plasmid (pFD6).
72h after transfection, cells were collected and lysed by three sequential
freeze–thaw cycles (−80/37 °C). The AAV vectors were puriﬁed using heparin
afﬁnity columns (GE HealthCare), concentrated using Amicon ultra-4 centrifugal
ﬁlter units with a 100,000 molecular weight cutoff (Millipore) and ﬁltered through
a 13 mm diameter 0.2 μm syringe ﬁlter. Genomic titers were determined on the
basis of an AAV2 ITR sequence-speciﬁc qPCR (Supplementary ref. 20), using a
LightCycler 480 Real-Time PCR System (Roche, Meylan, France).
In vitro validation of the rAAV-mediated gene silencing. Hippocampal cultures
(13 DIV) were infected with AAV vectors (5 × 109 genome copies per 60 mm
plate). 5 days after the infection with the shH1a-AAV or shCtrl-AAV, the primary
infected neurons were collected and the total RNA extractions were performed
using the Trizol reagent (Invitrogen) according to the manufacturer’s instruction.
The integrity of the RNA was checked by capillary electrophoresis using the RNA
6000 Nano Lab-on-a-Chip kit and the Bioanalyzer 2100 (Agilent Technologies,
Palo Alto, CA, USA). cDNA was synthesized from 2 µg of total RNA with Revert
Aid Premium Reverse Transcriptase (Fermentas, St. Leon-Rot, Germany) and
random primers (Fermentas).
QPCR was perfomed using a LightCycler 480 Real-Time PCR System (Roche,
Meylan, France). QPCR reactions were done in duplicate for each sample, using
transcript-speciﬁc primers, cDNA and LightCycler 480 SYBR Green I Master
(Roche) in a ﬁnal volume of 10 μl (Melting curve, 95 °C for 5 min and 45 cycles of
95 °C 15 s and 61 °C for 30 s).
Primer sequences for mouse Homer1a are Fwd: 5′-AATTTGAACCCACCGC
CTTA-3′ and Rev 5′GGTCATTTCGCTCACGTCTTC-3′. The PCR data were
exported and analyzed in an informatics tool (Gene Expression Analysis Software
Environment) developed at the NeuroCentre Magendie. For the determination of
the reference genes, the Genorm method was used. Relative expression analysis was
corrected for PCR efﬁciency and normalized against two reference genes
(mGADPH, Fwd: 5′-TCAAGAAGGTGGTGAAGCAG-3′ and Rev: 5′-TGGGAGT
TGCTGTTGAAGTC-3′) and mNono, Fwd 5′-CTGTCTGGTGCATTCCTGAA
CTAT-3′ and Rev 5′-AGCTCTGAGTTCATTTTCCCATG-3′). The relative level
of expression was calculated using the comparative (2-ΔΔCT) method and controls
were arbitrarily set at 1. Transduction of primary hippocampal cultures with
shH1a-AAV-resulted in a reduction of homer1a mRNA levels by 65–67% relative
to those transduced with shCtrl-AAV (Supplementary Fig. 15).
AAV vector administration. Brieﬂy, WT and Fmr1 KO mice (post natal age
21 days) were anaesthetized with an isoﬂuorane/air mix (3% for initial induction
and 1.5–2% for maintenance), head-ﬁxed in a stereotaxic apparatus (David Kopf
Instruments), and placed on a heating pad (HP-1M, Physitemp Instruments, Inc.)
connected to a controller (TCAT-2LV, Physitemp Instruments, Inc.) set to
maintain the body temperature at 37 °C. Three hundred nanoliters of either AAV-
shScr or AAV-shH1a were injected bilaterally into the dorsal hippocampus
(Supplementary ref. 21; mouse brain atlas; coordinates: −1.95 mm AP,± 1.25 mm
ML, −1.35 mm DV from bregma). The viruses were injected at the rate of
75 nL/min. The injections were performed using a 34-gauge needle (World Pre-
cision Instruments) attached to a 10 µL-NanoFil microsyringe (Nanoﬁl, World
Precision Instruments). The microsyringe was driven by an electronic micropump
system (UltraMicroPump, World Precision Instruments) connected to a micro-
processor controller (Micro4, MicroSyringe Pump Controller). Treatments (shCtrl
and shH1a) were randomly assigned to individual mice, and balanced within a
litter. Electrophysiological experiments began 4 weeks after virus infusion when
transgene protein expression had peaked to remain at stable levels (Supplementary
ref. 22). Behavioral testing started 9 weeks after virus infusion. Injection of AAV
vectors resulted in the efﬁcient infection of about 97% of CA1 neurons (Supple-
mentary Fig. 15).
Electrophysiological recordings of NMDAR currents. Acute hippocampus slices
were prepared from male 11–15-day-old WT and Fmr1 KO mice (for experiments
performed at University of Catania; Fig. 5, Supplementary Fig. 5). Brains were
removed and placed in oxygenated ice-cold artiﬁcial cerebrospinal ﬂuid (ACSF; in
mM: NaCl 124; KCl 3.0; NaH2PO4 1.2; MgSO4 1.2; CaCl2 2.0; NaHCO3 26;
D-glucose 10; pH 7.3), and transversal slices of dorsal hippocampus (300 µm thick)
were cut using a vibratome (Leica VT1200). Slices were allowed to recover for at
least 3 h at RT. For some experiments slices were incubated with 5–10 µM TAT-
mGluR5ct or TAT-mGluR5mu for 4 h at RT.
For electrophysiological recordings, slices were transferred to the recording
chamber and visualized using a Leica DMLFS microscope equipped with 20X/0.3
nA and 40×/0.80 nA objectives and differential interference contrast (DIC). A
tungsten monopolar electrode (WPI) was placed in the stratum radiatum to
stimulate Schaffer collaterals using negative current pulses (duration 0.3
milliseconds), delivered every 30 s by a stimulus generator (A310 Accupulser with
A360 stimulus isolator unit, WPI, USA). Stimulation intensity was set to induce
80% of maximal EPSC amplitude. Evoked EPSCs were recorded at RT from CA1
pyramidal neurons in the whole-cell patch-clamp conﬁguration at a holding
potential of −60 mV using an EPC7-plus ampliﬁer (HEKA, Germany). Current
traces were ﬁltered at 3 kHz and digitized at 10 kHz. The NMDA-to-AMPA ratio
(NMDA/AMPA) of evoked EPSCs was measured following standard procedures
(Supplementary ref. 23). Patch pipettes (open-tip resistance of 1.5–3MΩ) were
ﬁlled with intracellular solution containing cesium (130 mM) and
tetraethylammonium (TEA, 10 mM). Mixed NMDA/AMPA EPSCs were evoked in
ACSF containing bicuculline (5 µM) and glycine (10 µM). EPSCs were evoked
every 15 s and recorded at a holding potential of −90 mV, 0 mV, and +50 mV. For
NMDA/AMPA ratio measurements, at least twenty traces were averaged at holding
potential (HP) of −90 and +50 mV respectively. At a HP −90 mV, EPSCs were
exclusively mediated by activation of AMPA receptors (EPSCAMPA). The time to
peak of EPSCAMPA at HP of −90 mV was used to establish the time window for
measuring the peak EPSCAMPA at +50 mV. A complete decay to baseline of
EPSCAMPA at HP of −90 mV generally occurred 40 ms after the stimulus artifact.
This delay was used as a time window to measure the amplitude of the current
mediated by NMDAR (EPSCNMDA) at a HP +50 mV. The amplitude of EPSCNMDA
at +50 mV divided by the amplitude of EPSCAMPA at +50 mV was taken as the
NMDA/AMPA ratio.
For the LTD experiments, patch pipettes were ﬁlled with intracellular solution
containing (in mM): K-gluconate 140; HEPES 10; NaCl 10; MgCl2 2; EGTA 0.2;
QX-314 1; Mg-ATP 3.5; Na-GTP 1; pH 7.3. Slices were continuously perfused with
ACSF at a ﬂow rate of 1.0 ml/min. Following whole-cell access, the slice was
perfused with Mg2+-free ACSF containing CNQX (10 μM), glycine (10 μM) and
bicuculline (5 μM) to isolate EPSCNMDA. DHPG (100 µM) was dissolved in the
same ACSF and bath-applied for 5 min. Data were acquired and analyzed using
Signal software (Cambridge Electronic Design, England). EPSCNMDA amplitude
values were calculated as the difference between peak current and baseline,
averaged every minute, and expressed as percentage of control (calculated from
EPSCs recorded during at least 15 min prior to DHPG application). LTD
measurements on the same animal model (wild-type and Fmr1 KO mice on FVB
and C57BL6J background) have previously been performed in our laboratory47, 48,
demonstrating the validity of our DHPG-LTD protocol.
For the electrophysiological recordings of NMDAR currents from Fmr1 KO
mice (second generation) injected with AAV-sh H1a or AAV-scr, hippocampal
slices were prepared 4 weeks following viral injection (age of mice: 7–8 weeks) (for
experiments performed at IINS-CNRS; Fig. 6). Sagittal slices of dorsal
hippocampus (350-μm-thick) were cut in oxygenated ice-cold cutting solution (in
mM: Choline-Cl 110; KCl 2.5; NaH2PO4 1.25; MgCl2 7; CaCl2 0.5; NaHCO3 25;
D-glucose 20; Na-Ascorbate 5; Piruvate Acid 3, pH 7.3), and allowed to recover for
at least 30 min at 34 °C in oxygenated `recovery’ solution (in mM: NaCl 110; KCl
2.5; NaH2PO4 1.25; MgCl2 7; CaCl2 0.8; NaHCO3 25; D-glucose 20, Na-Ascorbate
1.3; Pyruvate Acid 3, pH 7.3). For electrophysiological recordings, slices were
superfused with ACSF at RT containing (in mM): NaCl 125; KCl 2.5; NaH2PO4
1.25; MgCl2 1.3; CaCl2 2.3; NaHCO3 25; D-glucose 20, pH 7.3. ACSF also
contained NBQX (20 μM), glycine (10 μM) and bicuculline (10 μM) to isolate
EPSCNMDA. Cells were visualized using a Nikon FN-S2N microscope equipped
with 10X/0.30 and 60X/1.0W objectives and DIC. A glass pipette (open-tip
resistance of 3.5–5MΩ) was placed in the stratum radiatum to stimulate Schaffer
collaterals with positive current pulses (duration 0.2 milliseconds), delivered every
20 s by a stimulus generator (DS3 constant current isolated stimulator, Digitimer
Ltd., England). Evoked EPSCNMDA were recorded at RT from CA1 pyramidal
neurons expressing GFP (successfully infected with AAV-sh H1a or AAV-scr) in
the whole-cell patch-clamp conﬁguration at a holding potential of +40 mV using
an EPC10 ampliﬁer (HEKA, Germany). Current traces were ﬁltered at 3 kHz and
digitized at 10 kHz. Patch pipettes (open-tip resistance of 2.5–4MΩ) were ﬁlled
with intracellular solution containing (in mM): CsMeSO3 133; HEPES 10; NaCl 4;
MgCl2 2; EGTA 0.2; Phosphocreatine 5; Na2-ATP 3; Na-GTP 0.4; pH 7.25. For
determining the EPSCNMDA Input/Output curve (I/O curve), at least three traces
were averaged for all stimulation intensities tested (range: 10–80 µA, 10 µA
intervals). For LTD experiments, DHPG (100 µM) was dissolved in the same ACSF
and bath-applied for 10 min. Data were acquired using PatchMaster software
(HEKA, Germany) and analyzed with Igor software (WaveMetrics, Inc., USA).
EPSCNMDA amplitude values were measured as the difference between peak current
and baseline, expressed as percentage of control (calculated from EPSCs recorded
during at least 10 min prior to DHPG application).
Behavioral testing. Male mice, obtained from harem breeding composed of two
Fmr1+/- breeding females and one male (as described above) were maintained in
their littermate groups following weaning. No animals were culled from the litters
prior to weaning. Male animals were housed in group-cages (42 × 26 × 15 cm; 3–5
individuals per cage). Cages were supplemented with minimal enrichment (cotton
nestlets) as required by French law. Every effort was made to ensure that these
littermate groups were balanced with respect to genotype (litters containing only
one genotype were excluded) and experimental groups were matched with respect
to age. Mice were acclimatized to an experimental animal facility for at least
8 weeks prior to behavioral testing (which was started at 12 weeks of age).
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Behavioral testing was performed in the following order: object-recognition test,
open ﬁeld, contextual fear conditioning. Behavioral phenotypes were initially
validated in the second-generation model using naïve animals (Fmr1 KO and their
WT littermates) of equivalent age, which had not undergone surgery to introduce
the AAV constructs required for knockdown experiments. All behavior experi-
ments were performed by a female member of the research team, during the light
phase of the cycle (between 08:30 and 18:00 hours) and, with the exception of the
open ﬁeld, analyzed blind to genotype. No statistical methods were used to pre-
determine sample sizes, but our sample sizes are similar to those used in previous
studies42, 43, 53.
One-trial-acquisition novel object-recognition (NOR) episodic memory was
assayed as described previously42 (see Fig. 6a) for a schematic representation). Our
testing conditions represent a modiﬁcation of the more ‘classical’ presentation of
the test in that mice were tested on an L-maze rather than an open ﬁeld or circular
arena to reduce anxiety and to encourage exploration70. The L-maze was made out
of gray non-reﬂective plastic and composed of two corridors (30 cm long × 4.5 cm
wide, and 15 cm high walls) set at a 90° angle. Testing was performed under
moderate illumination (40–50 lux, measured at the exterior of the maze, 5–10 lux
measured at the base of the maze) and each session was ﬁlmed (at a rate of 25
frames per second) for post hoc analysis. On day 1, mice were habituated for 10
min to the maze in which the task was performed. On the second day, mice were
put back in the maze for 10 min, two identical objects were presented and the time
that the mice spent exploring each object was recorded. The choice of object was
randomized, but balanced with respect to genotype. On the third day (24 h later)
subjects were again placed in the maze for 10 min, one of the familiar objects was
replaced with a novel object (the position of the novel object was randomized with
respect to the arm of the maze to control for any spatial component). Objects
presented were as follows: (1) glass screw cap bottle (6.8 cm tall, approximate
diameter 1.9 cm) composed of amber glass and plastic screw cap lid, and (2) plastic
Lego piece (3.3 × 3.3 × 2.5 cm). The grooved face of the Lego was presented to the
open side of the corridor. All objects were validated in prior tests using a separate
group of WT animals of the same genetic background (Supplementary Fig. 16).
The maze and objects were cleaned between each subject with 20% ethanol. Object
exploration was analyzed manually by an experienced observer and was deﬁned as
the orientation of the nose to the object at a distance of less than 2 cm. In each test
session, a discrimination index (DI) was calculated as the difference between the
time spent exploring the novel (TN) and the familiar object (TF) divided by the
total exploration time (TN+TF): DI = [TN−TF]/[TN+TF]. A higher discrimination
index is considered to reﬂect greater memory retention for the familiar object.
Analysis was performed blind to genotype and treatment. All the groups were age-
matched and counterbalanced for treatment.
Exploration in an open ﬁeld was performed in a separate experimental room,
using a 38.5 × 38.5 cm arena with 40 cm walls of dark blue Plexiglas. The ﬂoor of
the arena was white. The room illumination (measured at the center of the arena)
was ~ 40 lux. Mice were adapted to a fore-room of the experimental space for at
least 30 min prior to the session, although exploration took place in a rear zone,
separated by a door. No visual cues were presented. Each mouse explored the arena
for 30 min and the session was ﬁlmed (25 frames per second) and concomitantly
tracked using Ethovision XT acquisition and analysis software (Noldus). The
experimenter was not blinded to the genotype or experimental treatment, but all
analysis was performed in an automated manner by the software, using
predetermined parameters. Distance moved, and velocity, were determined using
center point tracking measures.
Contextual fear conditioning (CFC) was assayed as previously described42
(Fig. 6a) for a schematic representation). The task took place in a separate room, to
which the mouse has not previously been exposed, in a Plexiglas chamber (with a
17 × 25 ﬂoor and 22 cm walls (internal dimensions) equipped with overhead
infrared lighting. The chamber was composed of three transparent walls, and one
opaque wall, giving access to the visuo-spatial cues in the experimental room. The
illumination in the room was dim (5–10 lux measured within the chamber and
approximately 20 lux measured at the exterior of the chamber). The ﬂoor of the
conditioning chamber consisted of stainless-steel rods (2 mm diameter), spaced
5 mm apart and connected to a shock generator (Imetronic, Talence, France). The
four sides of the chamber and the rods of the ﬂoor were cleaned with 70% ethanol
before each trial. During conditioning, the mice explored the chamber for 2 min
and then received ﬁve 2-second-long unsignalled electric shocks (0.4 mA intensity),
at 1-minute intervals. The mouse was immediately returned to its home cage at the
end of the conditioning session. During the test phase (24 h after conditioning)
mice were put back in the same chamber for 6 min, without receiving any shock.
Both sessions were ﬁlmed (under infrared illumination) and freezing time was
scored, post hoc, by an experienced observer. Freezing was deﬁned as the absence
of any body movement beside respiration and was normalized by the duration of
the test session length to obtain a percent measure. In a subset of experiments,
freezing, as well as exploratory behavior (walking, rearing) on the ﬁrst day was also
scored. Experiments and analysis were performed blind to genotype and treatment.
All the groups were age-matched and counterbalanced for treatment.
Data representation and statistical analysis. Group values are presented as
mean± s.e.m. The data normality was tested using the D’Agostino-Pearson
omnibus normality test. Comparisons between groups for cumulative distribution
of instantaneous diffusion coefﬁcients and for co-localization data from
immunocytochemistry experiments were performed using Mann-Whitney test
(pair comparison) or Kruskal–Wallis followed by Dunn’s Multiple Comparison test
(group comparison). Comparisons of cumulative frequency distribution of
instantaneous diffusion coefﬁcients were performed using Kolmogorov-Smirnov
test. The comparison of the percentage of immobile and mobile receptors was
performed using Chi-square test with Yates’ correction. All of the other compar-
isons between groups were performed using parametric statistical tests, Student’s
t-test (pair comparison), one-way ANOVA (group comparison) followed by
Tukey’s Multiple Comparison test when appropriate. Signiﬁcance levels were
deﬁned as *P< 0.05, **P< 0.01, and ***P< 0.001.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within this article, its Supplementary Information ﬁles, or are
available from the corresponding authors upon reasonable request
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